DZD Research Highlighted in Two Publications on Plasmid-Mediated Antibiotic Resistance
June 2 2020

DZD technical expertise enables identification of novel mechanisms of antibiotic resistance using nanopore sequencing

Read More
DZD Awarded $6.2M Non-Dilutive Funding to Develop Rapid Antibiotic Resistance Diagnostic
May 11 2020

CARB-X selects Day Zero Diagnostics for their global portfolio of technologies to combat antibiotic-resistance

Read More
EpiXact® Helps Stop a Carbapenem-Resistant Acinetobacter baumannii Outbreak in a Burn ICU
February 28 2020

Research published in Infection Control and Hospital Epidemiology details use of patient and environmental whole genome sequencing to stop a CRAB outbreak

Read More
EpiXact® Used to Identify Drug-Resistant E. coli Transmitted by Fecal Microbiota Transplant
November 6 2019

EpiXact confirms cause of first patient death reported from an FMT procedure in research published in the New England Journal of Medicine

Read More
DZD Presents at Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
July 10 2019

CEO Jong Lee delivers DZD technology overview to Council

Read More
DZD Awarded SBIR Phase 1 Grant from NIH
July 10 2019

Funding supports development of algorithm for automated analysis of DNA sequencing data for outbreak detection

Read More
Top